Inhibition of bone resorption by Tanshinone VI isolated from Salvia miltiorrhiza Bunge

  • V. Nicolin | Nicolin@units.it Clinical Department of Biomedicine, University of Trieste, Italy.
  • F. Dal Piaz Clinical Department of Biomedicine, University of Trieste, Italy.
  • S. L. Nori Clinical Department of Biomedicine, University of Trieste, Italy.
  • P. Narducci Clinical Department of Biomedicine, University of Trieste, Italy.
  • N. De Tommasi Clinical Department of Biomedicine, University of Trieste, Italy.

Abstract

During the last decade, a more detailed knowledge of molecular mechanisms involved in osteoclastogenesis has driven research efforts in the development and screening of compound libraries of several small molecules that specifically inhibit the pathway involved in the commitment of the osteoclast precursor cells. Natural compounds that suppress osteoclast differentiation may have therapeutic value in treating osteoporosis and other bone erosive diseases such as rheumatoid arthritis or metastasis associated with bone loss. In ongoing investigation into anti-osteoporotic compounds from natural products we have analyzed the effect of Tanshinone VI on osteoclasts differentiation, using a physiologic three-dimensional osteoblast/bone marrow model of cell co-culture. Tanshinone VI is an abietane diterpene extracted from the root of Salvia miltiorrhiza Bunge (Labiatae), a Chinese traditional crude drug, ‘’Tan-Shen’’. Tashinone has been widely used in clinical practice for the prevention of cardiac diseases, arthritis and other inflammation-related disorders based on its pharmacological actions in multiple tissues. Although Tanshinone VI A has been used as a medicinal agent in the treatment of many diseases, its role in osteoclast-related bone diseases remains unknown. We showed previously that Tanshinone VI greatly inhibits osteoclast differentiation and suppresses bone resorption through disruption of the actin ring; subsequently, we intended to examine the precise inhibitory mechanism of Tanshinone VI on osteoclast differentiating factor. This study shows, for the first time, that Tanshinone VI prevents osteoclast differentiation by inhibiting RANKL expression and NFkB induction.

Downloads

Download data is not yet available.

Author Biography

V. Nicolin, Clinical Department of Biomedicine, University of Trieste

Clinical Department of Biomedicine

Published
2010-05-10
Section
Letters to the Editor
Keywords:
Tanshinone VI, osteoclastogenesis, Receptor Activator for Nuclear Factor ? B Ligand (RANKL)
Statistics
Abstract views: 367

PDF: 160
HTML: 1504
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Nicolin, V., Dal Piaz, F., Nori, S. L., Narducci, P., & De Tommasi, N. (2010). Inhibition of bone resorption by Tanshinone VI isolated from Salvia miltiorrhiza Bunge. European Journal of Histochemistry, 54(2), e21. https://doi.org/10.4081/ejh.2010.e21